News | November 07, 2022
Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
Subscribe To Our Newsletter & Stay Updated
